Please try another search
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company’s lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Name | Age | Since | Title |
---|---|---|---|
Bhaskar Chaudhuri | 69 | 2019 | Independent Director |
Andrew D. Goldberg | 42 | 2020 | Independent Director |
Rosemary A. Crane | 64 | 2021 | Independent Director |
Bobak R. Azamian | - | 2016 | Co-Founder, President, CEO & Chairman |
Elizabeth Yeu Lin | 46 | 2020 | Chief Medical Advisor & Director |
Wendy L. Yarno | 69 | 2020 | Lead Independent Director |
William J. Link | 78 | 2017 | Independent Director |
Scott W. Morrison | 66 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review